Related Experiment Videos
Single agent vs. combination chemotherapy for ovarian cancer
American Journal of Clinical Oncology
|February 1, 1985
Summary
A combination chemotherapy (CHF) showed higher response rates in advanced ovarian cancer compared to single-agent therapy (L-pam). Maximal surgical resection is crucial for improved outcomes in epithelial ovarian cancer patients.
Area of Science:
- Oncology
- Gynecologic Oncology
- Clinical Chemotherapy
Background:
- Advanced epithelial ovarian cancer presents a significant challenge in treatment.
- Chemotherapy regimens are a cornerstone in managing advanced ovarian cancer.
Purpose of the Study:
- To compare the efficacy of a combination chemotherapy regimen (Cytoxan, Hexamethylmelamine, Fluorouracil - CHF) against single-agent L-phenylalanine mustard (L-pam) in advanced ovarian cancer.
- To evaluate CHF as a second-line therapy for previously treated patients.
Main Methods:
- A randomized trial comparing CHF versus L-pam in 27 previously untreated patients.
- Administration of CHF as second-line therapy to 13 previously treated patients.
- Assessment of response rates, complete response, and disease-free intervals.
Main Results:
- The CHF combination therapy demonstrated an 85% response rate versus 57% for L-pam.
- Complete response rates were 50% for CHF compared to 17% for L-pam.
- All patients with <2 cm residual disease post-surgery responded, irrespective of therapy; 46% partial response to CHF in second-line setting.
Conclusions:
- Combination chemotherapy (CHF) appears more effective than single-agent L-pam for advanced ovarian cancer.
- Maximal surgical resection of residual disease is a critical factor for treatment success.
- CHF shows promise as a second-line treatment option.